UBS Group: The price reduction of the tenth round of collective procurement of Pharmaceuticals exceeded expectations, showing a cautious attitude towards the China generic drug market.

UBS Group released a research report stating that the tenth batch of national Pharmaceutical procurement in the mainland involves 62 types of Pharmaceuticals, with 385 products eligible for selection. Although the government has not disclosed the price reduction situation, according to Statistics, this time the reduction exceeds expectations, reaching 80% to 96%, and it is believed to be the largest reduction in history. The results of the Pharmaceutical procurement will be comprehensively implemented nationwide starting from April next year and will remain effective until the end of 2027. Overall, UBS Group believes that the results of the tenth batch of national Pharmaceutical procurement reflect China's tightening of the basic Medical Insurance Fund, and the government has also increased support for new drugs. Looking ahead, the bank holds a cautious attitude towards the prospects of China's generic drug market, and also anticipates.

AASTOCKSDec 19 09:49

SKB BIO-B (06990) has completed the subscription of 4.4239 million new domestic shares according to special authorization.

SKB BIO-B (06990) announced that all conditions for the subscription matter have been met, and the company has received...

Zhitong FinanceDec 18 18:10

SKB Biopharma Avails of 300 Million Yuan Structured Deposits From China's Industrial Bank

MT NewswiresDec 18 14:04

SKB BIO-B (06990) has subscribed to a total of 0.3 billion yuan in structured deposits with Industrial Bank.

SKB BIO-B (06990) announced that on December 17, 2024, the company signed with Industrial Bank...

Zhitong FinanceDec 17 23:00

J.P. Morgan gives Coronabo Biotechnology (06990.HK) an initial "Shareholding" rating with a Target Price of 240 yuan.

JPMorgan published a research report indicating an initial "Shareholding" rating for SKB BIO-B (06990.HK) with a target price of 240 yuan. SKB BIO was established in 2016, and currently, it has an antibody-drug conjugate (ADC) SKB264 in the China market, as well as eight ADCs undergoing clinical trials, along with three non-ADC cancer drugs currently under new drug application (NDA) approval in China. JPMorgan also mentioned that Merck (MRK.US) holds the rights for the development, use, manufacturing, and commercialization of SKB264 outside Greater China, and has initiated 10 projects.

AASTOCKSDec 17 10:02

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 14:21